Type II Diabetes
Our Clinic is currently
enrolling participants in four new type II diabetes
studies. The first is sponsored by Takeda
Pharmaceuticals and is designed to determine the
effectiveness of a new medication in preventing high
blood sugar and preserving pancreatic and metabolic
functions. Now enrolling patients ages 18-80 who have
been diagnosed with type II diabetes no less than three
months prior to enrollment. Patients may be using diet
and exercise only to control their diabetes, or be on a
stable dosing regimen of Metformin.
The second diabetes study is sponsored by Bristol Myers
Squibb and involves a new compound combination with
Metformin and/or TZD and/or Insulin therapy. Now
enrolling patients ages 18-77 with the intention of
assessing the effects of lowering blood sugars by
management of diabetic medications.
The third and fourth studies are being sponsored by
Glaxo Smith Kline and are intended to study and compare
the effects of two medications, one new and one already
approved, in lowering high blood sugars, lowering
lipids, and lowering body weight in patients who use
diet and exercise only to control their type II
diabetes.
Patients can benefit by participating in a number of
ways. First it provides comprehensive follow-up care for
your diabetes. It is also an opportunity for you to
learn more about diabetes and things you can do to keep
your blood sugar under control. This includes counseling
about diet and exercise. The screening process provides
an excellent overall health assessment and by being
involved, you make an important contribution to others
through the value of research to other patients. Study
stipends are available to participants who qualify.
Contact Janey
Troy for more information.
Menopausal
Symptoms:
This study monitors Vasomotor
Symptoms (VMS- hot flushes/night sweats) in post
menopausal women ages 40-65 who experience moderate to
extremely severe hot flushes or night sweats. Subjects
will receive 12 weeks of oral therapy. There are a total
of 9 scheduled clinical visits over a 20 week period.
Reimbursement offered to qualifying subjects. Contact
Lisa Galindo
for more information.
Insomnia:
Now enrolling ages adults (ages 18-64) with chronic
insomnia for a double-blind, placebo-controlled study to
demonstrate the subjective treatment effects of
Ramelteon on sleep using post-sleep questionnaires and
interactive voice recording systems. Participants will
receive placebo or study medication for 21 days for a
total study duration of 49 days over 6 visits.
Reimbursements offered to qualifying subjects. Contact
Lisa Galindo
for more information.
High Blood Pressure:
Now enrolling male and female patients age 18 or older
diagnosed with Essential Hypertension with the objective
of evaluating changes in 24-hour mean systolic blood
pressure by ambulatory blood pressure monitoring in
response to study medication compared to placebo and
Olmesartan. This study consists of 9 scheduled clinic
visits over a total of a 12 week period including a 4
week screening, 6 weeks on the study drug, and a one
week follow-up. Reimbursements offered to qualifying
subjects. Contact
Lisa Galindo for more information.
Upcoming Studies:
Migraine Headache Prevention,
Knee Osteoarthritis, Tendonitis.
Please Note:
All study participants receive at no
cost: Physical assessments, Laboratory tests, Patient
education, Diet counseling, X-rays, and medication. All
results will be shared with the patients’ Personal Care
Provider (PCP) upon
request. Stipends are usually based on the number of
visits and paid upon successful completion of the study.
Back to Top |
